Affymax (NASDAQOTH:AFFY) is starting 2013 in the best way possible and recently announced a deal with dialysis provider DSI Renal. Its drug, Omontys, is being used in dialysis centers, including some managed by Fresenius Medical Care (NYSE:FMS), and Affymax shareholders hope that the company can secure more lucrative deals in the coming months.

Despite Omontys' dosing advantage, however, biotech stalwart Amgen's (NASDAQ:AMGN) drug Epogen is still a formidable competitor in this space. The head-to-head competition for these anemia drugs is far from over, and, in the following video, health care analyst Max Macaluso weighs in on the debate.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.